BeiGene ends its Phase 3 lung cancer trial for ociperlimab after a futility analysis. No new safety concerns were found, and study results will be shared later.
MERCK & CO. INC. has a stellar value proposition. NYSE:MRK not only scores well in profitability, solvency, and liquidity but also maintains a very reasonable price point.
The U.S. stock market had a mixed session on Tuesday. The Nasdaq Composite climbed nearly 80 points, or 0.5%, closing at 18,271.86, while the Dow remained largely flat at 42,587.50. The S&P 500 edged up 0.2% to finish at 5,776.65. Amidst these fluctuations, certain stocks grabbed the attention of retail traders and investors throughout the day.
The Chinese company will receive $200 million upfront and will be eligible to earn up to $1.77 billion in milestone payments and royalties on net sales of the drug, if approved.
Mural Oncology ends nemvaleukin development for ovarian cancer after ARTISTRY-7 trial misses survival goals. Phase 2 trials for melanoma continue into 2025.
Summit Therapeutics' ivonescimab shows strong efficacy in trials, with Cantor Fitzgerald predicting a 50% market share in the $100B VEGF x PD-(L)1 space.
